Correlation Between Kymera Therapeutics and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kymera Therapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Kymera Therapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Blueprint Medicines.
Diversification Opportunities for Kymera Therapeutics and Blueprint Medicines
0.2 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Kymera and Blueprint is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Kymera Therapeutics and Blueprint Medicines
Given the investment horizon of 90 days Kymera Therapeutics is expected to under-perform the Blueprint Medicines. But the stock apears to be less risky and, when comparing its historical volatility, Kymera Therapeutics is 1.04 times less risky than Blueprint Medicines. The stock trades about -0.14 of its potential returns per unit of risk. The Blueprint Medicines Corp is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest 8,440 in Blueprint Medicines Corp on August 24, 2024 and sell it today you would earn a total of 1,317 from holding Blueprint Medicines Corp or generate 15.6% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Kymera Therapeutics vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Kymera Therapeutics |
| Blueprint Medicines Corp |
Kymera Therapeutics and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Kymera Therapeutics and Blueprint Medicines
The main advantage of trading using opposite Kymera Therapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Kymera Therapeutics vs. Foghorn Therapeutics | Kymera Therapeutics vs. Shattuck Labs | Kymera Therapeutics vs. Monte Rosa Therapeutics | Kymera Therapeutics vs. Nurix Therapeutics |
| Blueprint Medicines vs. Lyra Therapeutics | Blueprint Medicines vs. Hookipa Pharma | Blueprint Medicines vs. Cingulate Warrants | Blueprint Medicines vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |